News & Events CTI CEO to Chair Panel on Next Generation Cell and Gene Therapy in Oncology

CTI CEO to Chair Panel on Next Generation Cell and Gene Therapy in Oncology

October 1, 2018

FOR IMMEDIATE RELEASE [Covington, KY ~ October 1, 2018]  Timothy Schroeder, CEO of CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization, will chair a panel at the Alliance for Regenerative Medicine (ARM) Cell and Gene Meeting on the Mesa in La Jolla, CA.  The panel is titled, "Next Generation Cell and Gene Therapy in Oncology" and will be held on Thursday, October 4. The panel will focus on discussions around lessons learned from the recent approvals of the first cell and gene therapies in oncology and what improvements can be made to relevant processes moving forward.

"We are privileged to be a part of the ARM Cell and Gene Meeting on the Mesa, both as a moderator and sponsor of the meeting," remarks Schroeder. "CTI is an expert in regenerative medicine. We have contributed to the world's first approved cell and gene therapies, and about half of our current studies involve cell and gene therapies. We believe that this expertise and our partnership with the Alliance demonstrates our belief that diagnosis and treatment paradigms will change dramatically in the near future based on these advances."

ARM is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide.

Timothy Schroeder, CEO and Founder of CTI, has over 35 years of clinical, academic, and industry experience in global drug and device development programs. CTI, founded in 1999, is a multi-national research firm with associates in North America, Europe, Latin America and Asia-Pacific. The firm, which in one of the 20 largest CROs in the world and has supported more than 100 drug and device approvals, currently works on behalf of approximately 120 global pharmaceutical and biotechnology companies. Prior to founding CTI, Tim held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. Tim is currently a board member for over a dozen corporate and non-profit organizations, including Xavier University, which he attended. Tim was named as an EY Entrepreneur of the Year in 2015, as Top Leader by the Enquirer Media in 2016, and as Deal Maker of the Year in 2017 by the Association for Corporate Growth.

 

CTI CEO to Chair Panel on Next Generation Cell and Gene Therapy in Oncology

FOR IMMEDIATE RELEASE [Covington, KY ~ October 1, 2018]  Timothy Schroeder, CEO of CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization, will chair a panel at the Alliance for Regenerative Medicine (ARM) Cell and Gene Meeting on the Mesa in La Jolla, CA.  The panel is titled, "Next Generation Cell and Gene Therapy in Oncology" and will be held on Thursday, October 4. The panel will focus on discussions around lessons learned from the recent approvals of the first cell and gene therapies in oncology and what improvements can be made to relevant processes moving forward.

"We are privileged to be a part of the ARM Cell and Gene Meeting on the Mesa, both as a moderator and sponsor of the meeting," remarks Schroeder. "CTI is an expert in regenerative medicine. We have contributed to the world's first approved cell and gene therapies, and about half of our current studies involve cell and gene therapies. We believe that this expertise and our partnership with the Alliance demonstrates our belief that diagnosis and treatment paradigms will change dramatically in the near future based on these advances."

ARM is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide.

Timothy Schroeder, CEO and Founder of CTI, has over 35 years of clinical, academic, and industry experience in global drug and device development programs. CTI, founded in 1999, is a multi-national research firm with associates in North America, Europe, Latin America and Asia-Pacific. The firm, which in one of the 20 largest CROs in the world and has supported more than 100 drug and device approvals, currently works on behalf of approximately 120 global pharmaceutical and biotechnology companies. Prior to founding CTI, Tim held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. Tim is currently a board member for over a dozen corporate and non-profit organizations, including Xavier University, which he attended. Tim was named as an EY Entrepreneur of the Year in 2015, as Top Leader by the Enquirer Media in 2016, and as Deal Maker of the Year in 2017 by the Association for Corporate Growth.

 

Subscribe to our mailing list

* indicates required